Tuesday, September 4, 2012
Sophiris Bio Inc., of La Jolla, Calif., reported data from a Phase I/II safety study, in which PRX302 was well tolerated through three months following a transrectal injection.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.